Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety ...

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved ...

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among ...

Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

Number 5: A prospective cohort study found that switching back from the biosimilar SB2 to the reference infliximab did not affect clinical disease activity or safety in inflammatory bowel disease (IBD ...

The denosumab biosimilar market is poised for disruption with 3 FDA-approved biosimilars, at least 5 awaiting approval, and launches anticipated to start in May 2025, while ongoing patent litigation ...

Biosimilars offer a cost-effective alternative to traditional DMARDs, with similar clinical potency and toxicity, but face adoption barriers in pediatric rheumatology. The FDA approves biosimilars ...